Opus Genetics reports preliminary FY 2024 net loss of $56.8M, cash burn $25.6M

Opus Genetics, Inc.

Net loss for FY 2024 expected to be approximately $56.8 million.
Net cash used in operating activities for FY 2024 approximately $25.6 million.
Cash and cash equivalents balance as of Dec 31, 2024 approximately $30.3 million.
All figures are preliminary, unaudited and subject to change upon finalization of audited financials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.